Precipio's Tech Selected by the University of Kentucky for Study

Precipio (NASDAQ:PRPO) announced its ICE COLD-PCR technology was picked for a study to inspect the clinically actionable mutations in Non-Small Cell Lung Cancer at the University of Kentucky’s Markey Cancer Center.
As quoted in the press release:

“The study will focus on actionable mutations for non-small lung cancer in EGFR, KRAS and BRAF,” said Dr. Kurt B. Hodges, Director, Molecular Oncology Services, who will lead the study. “Our goal is to use this technology to identify patients with clinically actionable mutations in NSCLC and then monitor these patients for treatment response via resistance mutations to commonly prescribed NSCLC drugs. Our department has considered numerous technologies for this study, and concluded that Precipio’s ICE COLD-PCR™ (ICP) was the most suitable because ICP is a non-allele specific technology with a sensitivity that will allow our laboratory to cost-effectively pick up critical clinically actionable mutations at very low levels in plasma and test for these mutations at several time points over the course of therapy.”
The study is scheduled to commence during the fourth quarter of 2017 and is expected to enroll 100 patients. This research study investigates the potential for the technology as a cutting-edge, cost-effective solution that enriches mutations to achieve a high level of sensitivity. Given the design of research studies such as this to conduct repeat testing over time to monitor disease progression, there is a substantive need for an inexpensive, cost-effective solution that creates a feasible, economically viable application of the promise of liquid biopsies.

Click here to read the full press release.

Source: www.accesswire.com